The Antitrust condemns the Bracco group to pay a 150 thousand euro fine for misleading advertising. In more detail, the Competition Authority accuses the Italian pharmaceutical company of having distributed advertising brochures, deemed untruthful, intended for medical personnel concerning two food supplements (Cogiton and Stenovit). The report was made by competitor Sharper Healthcare. «For both products - reports the Antitrust - the conditions of effectiveness on the prevention and treatment of brain aging and diseases related to cellular neurodegeneration as well as cardiovascular diseases are considered misleading». In practice, according to the competition authority, both products mislead the recipients about the real characteristics and effects of its use.
Milan&Finance – 21 September 2010
